Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | DTYMK | P23919 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23802338 | 0.86 | GPR119 (0.45) | GPR119NAMPTNR1H2POLBIDO1 | |
| SCHEMBL18497404 | 0.85 | GPR119 (0.47) | GPR119NAMPTNR1H2POLBIDO1 | |
| SCHEMBL23802304 | 0.80 | GPR119 (0.49) | GPR119NAMPTNR1H2POLBIDO1 | |
| SCHEMBL2996726 | 0.79 | GPR119 (0.50) | GPR119NAMPTNR1H2POLBFAAH | |
| SCHEMBL23802588 | 0.77 | GPR119 (0.49) | GPR119NAMPTNR1H2POLBIDO1 | |
| SCHEMBL27037135 | 0.77 | NR1H2 (0.55) | GPR119NAMPTNR1H2ALOX5APFEN1 | |
| SCHEMBL23802302 | 0.77 | GPR119 (0.46) | GPR119NAMPTNR1H2POLBIDO1 | |
| SCHEMBL23802320 | 0.76 | GPR119 (0.48) | GPR119NAMPTNR1H2POLBIDO1 | |
| SCHEMBL23802337 | 0.76 | GPR119 (0.48) | GPR119NAMPTNR1H2POLBFAAH | |
| SCHEMBL23298015 | 0.76 | NR1H2 (0.54) | GPR119NAMPTNR1H2IDO1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210276977-A1 | BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | ALKERMES, INC. | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276977-A1 | BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC2, HDAC11 | GPR119 1656/4885NAMPT 334/4885NR1H2 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.